1 , peaked at 7 days, and expression persisted
for at least 4 weeks after 2 h of MCAo.
2 ly therapeutic enzyme activity is maintained
for at least 2 weeks after a single dose in most patient
3 and reduced leukostasis and vascular leakage
for at least 4 weeks after a single injection in the ret
4 Serum was collected
for at least 2 weeks after administration of MTX-CPG2 to
5 Blood B cells were absent
for at least 39 weeks after anti-CD19-CAR-transduced T-c
6 Elective surgery should be postponed
for at least 4 weeks after bare metal stent implantation
7 athymic progenitor niches remain unsaturated
for at least 10 weeks after BMT.
8 populate the thymus are poorly reconstituted
for at least 4 weeks after BMT.
9 elevated in a subset of spinal cord neurons
for at least 12 weeks after cessation of topotecan treat
10 he suppression of DC-derived IL-12 persisted
for at least 6 weeks after CLP and was not due to immuno
11 r nuclear layers of the retina, and remained
for at least three weeks after damage.
12 n pancreatic islets were functional in vitro
for at least 2 weeks after encapsulation.
13 tein remained significantly above background
for at least 2 weeks after exposure along with increased
14 rane domains at remyelinated nodes persisted
for at least 8 weeks after GFP-OEC transplantation.
15 tinually produced from infected CaCo-2 cells
for at least 6 weeks after infection.
16 els of mutant IkappaB protein were expressed
for at least 7 weeks after infection.
17 ected with HCV and support virus replication
for at least 8 weeks after infection.
18 of plasma viremia (<400 HIV-1 RNA copies/mL)
for at least 48 weeks after initiation of antiretroviral
19 production of new glial cells which survive
for at least 3 weeks after injury.
20 minal tract), (2) persistent ipsilateral Fos
for at least 4 weeks after injury in dynorphin (Dyn)-ric
21 ral RNA persisted in musculoskeletal tissues
for at least 3 weeks after inoculation.
22 otection from viral shedding after challenge
for at least 6 weeks after inoculation; protection was c
23 ive for the prevention of pulmonary embolism
for at least 5 weeks after placement in swine.
24 inued, marked thrombin generation that lasts
for at least 2 weeks after PTCA.
25 and a- and b-wave amplitudes, was documented
for at least 4 weeks after RHP.
26 -mediated immune responses to viral antigens
for at least 17 weeks after SIV challenge.
27 Remarkably, the improvement persisted
for at least 3 weeks after stimulation.
28 Thirteen patients were followed
for at least 48 weeks after stopping therapy and 9 under
29 Observations were made
for at least 10 weeks after surgery.
30 The sprouted axons persisted in cortex
for at least 5 weeks after terminating exogenous BDNF de
31 Improvements in memory persisted
for at least 3 weeks after the arrhythmic hamsters were
32 eveloped after nerve cuff placement remained
for at least 3 weeks after the nerve cuffs were removed,
33 gG levels persisted in all responding groups
for at least 7 weeks after the boost (week 22).
34 ferred by NAPE-expressing bacteria persisted
for at least 4 weeks after their removal from the drinki
35 This effect persisted
for at least 4 weeks after training.
36 dase activity were detectable histologically
for at least 20 weeks after transplant, and beta-galacto
37 d result in good saturation of Tac receptors
for at least 12 weeks after transplantation.